(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 12.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Innoviva's revenue in 2025 is $370,229,000.On average, 2 Wall Street analysts forecast INVA's revenue for 2025 to be $24,142,720,253, with the lowest INVA revenue forecast at $24,009,745,914, and the highest INVA revenue forecast at $24,275,694,593. On average, 2 Wall Street analysts forecast INVA's revenue for 2026 to be $28,158,104,160, with the lowest INVA revenue forecast at $27,742,480,573, and the highest INVA revenue forecast at $28,573,727,748.
In 2027, INVA is forecast to generate $33,142,751,263 in revenue, with the lowest revenue forecast at $33,142,751,263 and the highest revenue forecast at $33,142,751,263.